Please ensure Javascript is enabled for purposes of website accessibility

Hematology-Focused Biotech Imara to IPO Soon

By Brian Orelli, PhD - Updated Mar 6, 2020 at 6:48AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company has set terms for its initial public offering.

Imara, which is developing a drug for sickle cell disease and beta thalassemia, has set the terms for its initial public offering (IPO), with shares expected to sell for $16 to $18 each. The company could raise up to $80 million through the IPO, helping fund its drug IMR-687.

The biotech is currently running a phase 2a clinical trial testing IMR-687 in patients with sickle cell disease. Interim results presented last year showed the drug produced a 110% increase in the percentage of red blood cells that contain fetal hemoglobin. Low hemoglobin is what causes red blood cells to sickle.

In the first half of this year, Imara plans to start a phase 2b clinical trial in sickle cell disease and a separate phase 2b study in beta thalassemia.

Sickled red blood cells

Image source: Getty Images.

If IMR-687 makes it to market, it'll likely have competition from bluebird bio's (BLUE -2.39%) gene therapy Zynteglo, which is FDA approved for beta thalassemia and is far ahead of Imara in sickle cell disease. And there's a laundry list of other drugmakers developing gene-editing approaches to treat both diseases, including CRISPR Therapeutics (CRSP -0.27%) and its partner, Vertex Pharmaceuticals (VRTX 1.23%), which reported promising results in the first two patients in the study.

IMR-687 is taken orally, while gene therapies require a procedure that's similar to a bone marrow transplant, so the drug might be preferred by patients with mild versions of the disease.

Shares of Imara are expected to trade on the Nasdaq under the symbol "IMRA." A date for the IPO hasn't been set yet.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Vertex Pharmaceuticals Incorporated Stock Quote
Vertex Pharmaceuticals Incorporated
$258.59 (1.23%) $3.14
bluebird bio, Inc. Stock Quote
bluebird bio, Inc.
$3.27 (-2.39%) $0.08
CRISPR Therapeutics Stock Quote
CRISPR Therapeutics
$56.34 (-0.27%) $0.15

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/21/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.